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Abstract
Radioiodine-131 (I-131) is used in the treatment of thyroid diseases: hyperthyroidism and 
differentiated thyroid cancer (DTC: papillary, follicular, Hurthle cell cancer). Treatment 
success depends on several factors. The most fundamental factor affecting the success of 
treatment is the susceptibility to target tissue I-131. In patients with differentiated thy-
roid cancers following total thyroidectomy, I-131 is given for ablation of residual thyroid 
 tissue and treatment of metastatic disease. Physical and biological characteristics of I-131, 
uptake and effect mechanisms of the iodine in the thyroid follicular cells, indications 
and contraindications for I-131 therapy, patient preparation and administration of I-131, 
follow-up and precautions on possible side effects, and an overview on the clinical stud-
ies about I-131 therapy are presented.
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1. Introduction
Radioiodine-131 (I-131) is successfully used in treatment of thyroid diseases: hyperthyroid-
ism and differentiated thyroid cancer for several years. I-131 is available as sodium iodine 
in gelatine capsules and drinking solution for oral application and intravenous injections. 
Advantages of this therapy are good tolerability, easy application, safety, and efficacy of treat-
ment. The critical organ for I-131 is the thyroid gland. I-131 is taken up by follicular cells. 
Retention of I-131 in the cells depends on the metabolic activity of the cells. I-131 simultane-
ously emits two types of radiation: beta minus (β−) radiation used for the therapy and gamma 
(γ) used for diagnosis. Due to the penetration of beta particles in the tissue, damaging effect 
of β− radiation is limited to thyroid cells. The physical and biological characteristics of I-131, 
uptake and effect mechanisms of the iodine in the thyroid follicular cells, indications and con-
traindications for I-131 therapy, patient preparation and administration of I-131, follow-up 
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and precautions on possible side effects, and an overview on the clinical studies about I-131 
therapy are presented under this title.
2. Epidemiology
Thyroid cancer constitutes 1.4% of all cancers and 15% of all endocrinologic malignancies. 
Thyroid cancer is responsible from 0.2 to 0.5% of cancer-related death. About 90–95% of thy-
roid cancers are differentiated thyroid cancers of follicular cell origin. Annual incidence is 
1.2–2.6/100,000 in men and 2.0–3.8/100,000 in women. Mortality rates have been reported as 
0.2–1.2/100,000 in men and 0.4–2.8/100,000 in women [1].
3. Treatment options: role of radioiodine
Front-line therapy of differentiated thyroid cancer (DTC) is surgery. Because multifocality 
and multicentricity is frequent, total or near-total thyroidectomy is the treatment of choice. 
Samaan et al. have reported that recurrence rates were lower and survival rates were higher 
in total thyroidectomized patients [2]. Following total thyroidectomy, I-131 is given for abla-
tion of residual thyroid tissue and treatment of metastatic disease. To achieve a successful 
ablation and treatment, I-131 should be taken up by residual thyroid and metastatic tumors. 
The function of cancerous follicular cells is poorer than normal follicular cells. While normal 
thyroid tissue concentrates 0.5–1.0% of the administered I-131 dose, cancerous cells concen-
trate 0.01–0.02%.
Papillary cancer (the largest histopathologic group of thyroid cancers), follicular cancer, less 
than 10% of Hurthle cell variant papillary cancer, and mixed variant medullary cancer show 
I-131 uptake [3]. Ablation is defined as the radioiodine therapy given for destruction of func-
tional residual thyroid tissue in or out of the thyroid bed. Therapy is the term used for ster-
ilization of residual functional tumoral cells. As the volume of residual thyroid decreases, 
success of ablation increases. If residual thyroid tissue weighed <2 grams (gr), ablation effi-
ciency was reported as 94%, while this rate may fall as low as 64% in larger residues [4].
The European Association of Nuclear Medicine (EANM) recommends I-131 ablation for all 
differentiated thyroid cancer patients who have a tumor size >1 cm [5]. For patients with 
tumor size smaller than <1 cm with no other risk factors like capsular invasion, lymphovascu-
lar invasion, lymph node (LN) or distant metastasis, history of radiation exposure, and diffuse 
sclerosing subtypes, radioiodine ablation is debatable. The American Thyroid Association 
(ATA) does not recommend radioiodine in low-risk disease [6].
Ablation provides higher thyroglobulin (Tg) sensitivity, treatment of undetectable micrometa-
static disease, and a higher survival. Increase in thyroid-stimulating hormone (TSH) levels for 
ablation helps detection of metastatic disease on the postablative scan. In a prospective study of 
25 years of follow-up, it was reported that none of the patients who were totally ablated died of 
thyroid cancer, but in seven patients in whom ablation failed, the reason of death was thyroid 
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cancer [7]. Thyroid hormone replacement may not be started after surgery to achieve high TSH 
levels before I-131 therapy performed 4–6 weeks later [8, 9]. However, because euthyroidism 
augments tissue repair and prevents from postsurgical complications, tetraiodothyronine (T4) 
replacement therapy is generally started after total thyroidectomy [10].
4. Patient preparation for radioiodine therapy
T4 is stopped before radioiodine therapy and triiodothyronine (T3) can be started instead 
(25–75 μg/day), making sure that T3 is also withdrawn 2 weeks before I-131 administration 
[10]. The reason why T3 is given is that T3 has a shorter half-life than T4 (0.8 days versus 7 
days) and yields a faster TSH elevation after withdrawal compared to T4. Thus, hypothyroid 
period is shortened, and potential tumor growth rate stimulated by TSH is decreased.
Low-iodine diet is recommended for 3 weeks before radioiodine treatment, and drugs with 
stable iodine content should be ceased (Tables 1 and 2).
In cases of inadequate TSH elevation (pituitary disease, pituitary insufficiency of the elderly, 
extensive functioning thyroid cancer metastasis), recombinant human TSH (rhTSH: thyrotro-
pin alpha, Thyrogen®) can be used. 0.9 mg rhTSH is intramuscularly injected for two consecu-
tive days. Twenty-four hours later than the second dose of rhTSH administration, I-131 is 
given orally. Its safety and efficacy have been found noninferior to endogenous hypothyroid-
ism [11, 12]. There are a few publications mentioned in the use of rhTSH after redifferentiation 
therapy with retionic acid (13-cis-retinoic acid, isotretinoin) in undifferentiated thyroid cancer 
to increase radioiodine uptake [13, 14].
Preablative TSH and Tg levels are measured. If TSH is >30 μU/ml, then I-131 can be given 
[10]. Thyroglobulin is a glycoprotein produced by functioning follicular cells. Detectable Tg 
after total thyroidectomy is a marker of persistent or recurrent diseases. In subtotal thyroid-
ectomized patients, Tg measurement is not reliable. Thyroglobulin levels should not be used 
as a single criterion for determining necessity of radioiodine treatment. However, Tg levels 
Iodized salt
Milk and derivatives (cheese, yoghurt, ice-cream, etc.)
Seafood
Processed meat products (salami, sausage, etc.)
Packed food (chips, cookies, biscuits, etc.)
Canned vegetables and fruits
Green vegetables (spinach, lettuce, etc.)
Red pepper
Red food dye
Table 1. Avoided food.
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>5–10 mg/dL point out that there exists an amount of functioning thyroid tissue to be ablated. 
Conversely, Tg < 1 ng/dL does not exclude radioiodine avid disease either [6].
Patients should be fasting for 2–4 hours before I-131 administration. The aim of fasting is to 
increase I-131 absorption and decrease risk of vomiting.
5. Radioiodine for ablation
Ablation doses are still a matter of debate. Beierwaltes et al. have reported that 3.7 GBq (100 mCi) 
I-131 ablates 85% of thyroid remnants [15]. Lower doses of 1.11 GBq (30 mCi) have been shown 
to be noninferior; however, there are conflicting results [16–19]. There are three approaches 
for determination of I-131 dose: low dose, fixed high dose, and optimal dose. Low dose refers 
to 1.11 GBq (30 mCi). If ablation could not be maintained by a single dose, repeated doses can 
be given by 3–6 months of intervals. Although it depends on local radiation protection rules, 
hospitalization can be avoided in some regions in the world by dose administration. Lower 
whole-body and gonadal radiation doses and lower risk of side effects of radioiodine are 
other advantages. However, if ablation failed, repeated therapies cause long span of hypothy-
roidism. Stunning is another important disadvantage in secondary ablation doses. Stunning 
is defined as decrease of radioiodine uptake due to previous I-131 administrations for diag-
nostic or treatment purposes. Park et al. have reported that diagnostic doses between 111 
and 370 MBq (3–10 mCi) I-131 caused stunning in a dose-dependent manner and this effect 
was overcome by the use of I-123 [20]. I-123 is a good alternative for scanning before I-131 
treatment if preablative whole-body scan is necessary, as it gives a lower absorbed dose and 
provides better image quality and high accuracy [21]. Fixed high doses for ablation are given 
as 277.5–555 MBq (75–150 mCi). This is an effective and easy method to achieve ablation at a 
single step, and hypothyroid state is shorter. Nemec et al. have reported that over 85% of the 
patients ablation was maintained eradicating the need for a second dose [22].
Approach of optimal dose ablation aims to provide ablation of the whole residual thyroid tis-
sue with the lowest radiation burden possible to extrathyroidal tissues [9]. For optimal dose 
Drug or molecule Recommended withdrawal time
Propylthiouracil, perchlorate, sulfonamides, tapazole, thiocyanate, penicillin, 
nitrates, antihistamines, and anticoagulants
1 week




Tetraiodothyronine (T4) 4–6 weeks
Amiodarone 4–12 weeks
Intravenous contrast agents 1–3 weeks
Oral cholecystographic agents 2–3 weeks
Table 2. Drugs decreasing radioiodine uptake in thyroid cells and recommended withdrawal time.
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calculation, formulations considering the weight of residual tissue and radioiodine uptake 
are used:
  Administered activity :  Planned dose × Gland weight × 6.67   _____________________________________  
 T eff × % uptake (24 hour)  (1)
  Absorbed dose :  Peak activity of the lesion ×  T eff × 1.443   _________________________________________________Tissue weight (2)
Teff: effective half-life
Dose calculation approach may be theoretically reasonable, but it is troublesome to calculate 
biological half-life by collecting samples of urine and gaita from the patients, and interob-
server variabilities in the measurement of residual tissue may cause mistakes. Ablation suc-
cess rates of fixed high-dose and dose calculation methods are similar. So, fixed high-dose 
administration is the preferred method with regard to dose calculation.
As I-131 is primarily excreted by urine, dose reduction in renal failure and dialysis should 
be concerned. Kaptein et al. have reported that in patients who undergo continuous abdomi-
nal peritoneal dialysis, radioiodine clearance decreased five times and in order to optimize 
whole-body and bone marrow dose, radioiodine dose should be reduced by 5 [23]. By dialysis, 
effective half-life is shortened and tumoral dose is decreased. I-131 administration should be 
postponed after dialysis. Other situations which cause a change in distribution and increase 
retention are peritoneal ascites, pleural effusion, and extensive functioning metastasis.
Whole-body I-131 scan should be performed on postablative 2–6 days or after whole-body 
radiation dose is measured below 370 MBq (10 mCi). This study is important in determination 
of prognosis, as the absence of detectable metastases decreases risk of recurrence.
6. Adjuvant radioiodine therapy and treatment of metastasis
Postsurgical administration of I-131 provides a significant decline in recurrence rates. This is 
attributable to adjuvant usage of radioiodine which aims destruction of unknown microme-
tastasis rather than ablation of residual thyroid [10, 24, 25]. For apparent metastases detected 
before surgery or in the follow-up, the primary requirement is radioiodine avidity. Fixed high 
doses are frequently used for treatment of thyroid cancer metastases (Table 3).
Another approach in treatment of metastasis is dose calculation according to the upper limits 
of blood and whole-body dosimetry and quantitative tumor or lesional dosimetry.
Five hundred fifty-five MBq (150 mCi) treats 95% of metastases in the thyroid bed. Upper 
limit of radioiodine dose for a single administration is determined as 740 MBq (200 mCi), set 
for a blood radiation dose below 200 rad (200 cGy) (maximum tolerated dose) [9]. In order to 
provide enough radiation to the tumor, formulations concerning radioiodine uptake value, 
tumor volume, and effective half-life are used:
  D (Gy / mCi)  :  % uptake  
(24 hr) × 152 ×  T eff   ____________________________________ Tumor mass  (gram)  (3)
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For lymph node metastases, surgery is the first treatment to try, especially in bulky disease. 
Small LN metastases with adequate radioiodine uptake can be treated with I-131.
Adjunctive radioiodine therapy after surgery is generally recommended. Published in a ret-
rospective series is that, a delay in radioiodine therapy for 6 months or more caused disease 
progression, and survival rates were decreased [26].
Cervical lymph node involvement doesn’t increase mortality but morbidity. The lymph node 
is common especially in papillary carcinoma, and its incidence has been reported 48 and 17% 
below and over age 40 [27]. Recurrence rates are twice as much in nodal metastatic disease 
[10]. It has been proved that recurrent metastases decrease by treatment of metastatic lymph 
nodes by I-131 [28].
Distant metastasis significantly reduces survival rates. Mortality rates are higher in brain and 
skeletal metastasis. In a series, distant metastasis was detected in 19% of the patients who 
received radioiodine treatment. Of these, 44% were to lungs, 31% to mediastinum, and 23% 
to the skeletal system [29]. Pulmonary metastasis is seen in 2–12% of the cases, and its fre-
quency is less in patients who had undergone total thyroidectomy and radioiodine therapy 
[28, 30].
Pulmonary metastasis occurs by lymphogen, whereas skeletal metastasis occurs by micro-
invasion and hematogen way. The fact that there is a correlation between cervical lymph 
node and pulmonary metastasis and a reverse correlation between nodal and skeletal metas-
tasis supports this opinion. Skeletal metastasis has a worse prognosis than lung metastasis. 
Skeletal metastasis is seen five times more frequent in follicular carcinoma patients than in 
papillary carcinoma patients and in the elderly. The cranium, vertebral column, and costae 
are generally involved [22].
3.7–7.4 GBq (100–200 mCi) I-131 is recommended to be administered by 6–12 months of inter-
vals. Therapy should be continued till all radioiodine avid lesions are ablated or an intol-
erable complication is likely to arise. For iodine avid disease, there is no upper limit for 
cumulative dose. However, due to high complication risks, doses over 22.2 GBq (600 mCi) 
should be evaluated on a patient basis. If complete response can’t be achieved but disease 
stays stable, then intervals between doses can be extended, or therapy can be stopped with 
close monitoring [5].
Metastatic region Dose GBq (mCi)
Residual thyroid cancer in the thyroid bed 3.7 (100)
Cervical LN metastases 5.55–6.47 (150–175)
Lung metastases 6.47–7.4 (175–200)
Distant metastases 7.4 (200)
Table 3. Doses used in the treatment of functioning thyroid cancer metastasis.
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7. Differentiated thyroid carcinoma derived from ectopic tissue
Sublingual area is the most common place for ectopic thyroid development. Insufficient T4 
production in ectopic tissue may cause TSH elevation and thus hyperplasia by stimulation. 
Long-term and intense TSH stimulation is blamed for carcinoma development in these cases. 
Thyroglossal canal originated papillary carcinoma may have an invasive character in 10% of 
the cases [31]. In 3% of the cases, ectopic thyroid tissue is found in ovarian teratoma (struma 
ovarii). Low-grade malignant tumor may arise from struma ovarii (5–20%), and some may 
metastasize [32]. Although management approaches are still uncertain, treatment of cancer of 
an aberrant thyroid tissue is the excision of the tumor followed by radioiodine therapy.
8. Contraindications
Absolute contraindications are pregnancy and nursing. If I-131 administration is essential, 
then nursing should be stopped [33, 34]. I-131 passes through the placenta and concentrates 
in fetal thyroid (<12 weeks). This causes serious hypothyroidism. Maternal bladder activity 
also causes fetal irradiation. Pregnancy should be avoided for 6–12 weeks after radioiodine 
therapy. Other relative contraindications for I-131 are bone marrow depression, pulmonary, 
salivary gland and renal function interruption, possibility of severe edema, and compression 
symptoms in brain metastasis [5].
9. Complications
There are acute (first 3 months) and chronic (later than 3 months) complications of radioio-
dine therapy. Acute complications are sialadenitis (most frequent), radiation parotitis and 
thyroiditis, metallic taste, gastrointestinal symptoms like nausea and vomiting due to radia-
tion gastritis, transient bone marrow depression (anemia in 36% of the patients, leukopenia 
10%, thrombocytopenia 3%), radiation pneumonitis and pulmonary fibrosis, radiation cysti-
tis, transient amenorrhea (secondary to pituitary-gonadal hormonal axis), decreased testicular 
function or fertilization, cerebral edema or spinal compression in metastatic cases, keratocon-
junctivitis, and decreased lacrimal function [35]. Chronic complications include secondary 
malignancies most frequently leukemia, myeloid leukemia, less frequently bladder cancer, 
salivary gland neoplasia, hypo- and hyperparathyroidism, and hypothyroidism [36–38].
10. Radioiodine therapy of pediatric differentiated thyroid cancer
Prognostic factors in differentiated thyroid cancer of the thyroid are not very well known 
because it is a relatively rare entity (3–4%) compared to thyroid cancer of the adults. In 
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 long-term follow-up, survival rates are found to be high despite increased rates of local recur-
rences and distant metastasis. Neck and pulmonary metastases concentrate and respond to 
radioiodine well [10]. Aggressive surgery followed by radioiodine is generally the preferred 
treatment option [39]. Radioiodine decreases recurrence in patients with known residual 
disease [40]. Disease-free survival rates are shown to be improved by radioiodine ablation 
without any significant increase in the risk of secondary malignancies [41]. I-131 treatment is 
recommended in radioiodine avid unresectable locoregional or distant metastasis [42].
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